Ranked #1 Children's Hospital by U.S. News & World Report
MyPatients provides referring primary care providers with secure access to their patients’ information.
Boston Children's has launched the world's 1st program dedicated to offering hand transplants to children who qualify.
Innovation insider is a semi-monthly e-newsletter analyzes innovations at Boston Children’s, other academic medical centers and from industry.
Read the latest blog by a Boston Children's doctor, clinician or staff member.
There are many ways you can help children and their families get the care they need.
Burkitt's lymphoma (also called small noncleaved cell lymphoma) is a type of non-Hodgkin lymphoma, a cancer in the lymphatic system.
Non-Hodgkin lymphoma causes the cells in your child’s lymphatic system to abnormally reproduce, eventually causing tumors to grow.
Non-Hodgkin disease cells can also spread to other organs and tissues in the body.
Non-Hodgkin lymphoma is the third most common childhood cancer.
It occurs most often in children between the ages of 7 and 11, but can occur at any age from infancy to adulthood.
Non-Hodgkin lymphoma affects males almost three times more often than females, and is more common among Caucasian children than among African-American children and children of other races.
Patients with Burkitt's lymphoma are treated through the Lymphoma Treatment Program at Dana-Farber/Boston Children's Cancer and Blood Disorders Center, an integrated pediatric hematology and oncology partnership between Dana-Farber Cancer Institute and Boston Children’s Hospital. We utilize the expertise of both Boston Children's Hospital, ranked the #1 children's hospital in the country, and the Dana-Farber Cancer Institute, a nationally recognized leader in cancer care and a member of the Dana-Farber/Harvard Cancer Center. Members of our physician team all have specific expertise in pediatric lymphomas. Specific disciplines include oncology, radiation oncology, surgery, interventional and diagnostic radiology, and hematopathology. We treat all forms of non-Hodgkin lymphoma and related disorders.
The future of pediatrics will be forged by thinking differently, breaking paradigms and joining together in a shared vision of tackling the toughest challenges before us.”